KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $2.3 billion.

  • Ionis Pharmaceuticals' Cash & Current Investments fell 9.79% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 billion, marking a year-over-year decrease of 1.39%. This contributed to the annual value of $2.3 billion for FY2024, which is 1.44% down from last year.
  • As of FY2024, Ionis Pharmaceuticals' Cash & Current Investments stood at $2.3 billion, which was down 1.44% from $2.3 billion recorded in FY2023.
  • In the past 5 years, Ionis Pharmaceuticals' Cash & Current Investments registered a high of $2.3 billion during FY2023, and its lowest value of $1.9 billion during FY2020.
  • In the last 3 years, Ionis Pharmaceuticals' Cash & Current Investments had a median value of $2.3 billion in 2024 and averaged $2.2 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first fell by 24.29% in 2020, then increased by 17.33% in 2023.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Cash & Current Investments stood at $1.9 billion in 2020, then grew by 11.76% to $2.1 billion in 2021, then declined by 6.06% to $2.0 billion in 2022, then increased by 17.33% to $2.3 billion in 2023, then declined by 1.44% to $2.3 billion in 2024.